‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA DOI Creative Commons
Peter Parry,

Astrid Lefringhausen,

Conny Turni

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(8), P. 2287 - 2287

Published: Aug. 17, 2023

The COVID-19 pandemic caused much illness, many deaths, and profound disruption to society. production of ‘safe effective’ vaccines was a key public health target. Sadly, unprecedented high rates adverse events have overshadowed the benefits. This two-part narrative review presents evidence for widespread harms novel product mRNA adenovectorDNA is in attempting provide thorough overview arising from new technology that relied on human cells producing foreign antigen has pathogenicity. first paper explores peer-reviewed data counter attached these technologies. Spike protein pathogenicity, termed ‘spikeopathy’, whether SARS-CoV-2 virus or produced by vaccine gene codes, akin ‘synthetic virus’, increasingly understood terms molecular biology pathophysiology. Pharmacokinetic transfection through body tissues distant injection site lipid-nanoparticles viral-vector carriers means ‘spikeopathy’ can affect organs. inflammatory properties nanoparticles used ferry mRNA; N1-methylpseudouridine employed prolong synthetic function; biodistribution DNA codes translated spike proteins, autoimmunity via contribute harmful effects. reviews autoimmune, cardiovascular, neurological, potential oncological effects, autopsy spikeopathy. With gene-based therapeutic technologies planned, re-evaluation necessary timely.

Language: Английский

FOXO transcription factors as therapeutic targets in human diseases DOI Creative Commons
Alba Orea-Soufi, Jihye Paik, José Bragança

et al.

Trends in Pharmacological Sciences, Journal Year: 2022, Volume and Issue: 43(12), P. 1070 - 1084

Published: Oct. 21, 2022

Language: Английский

Citations

93
Blood-to-brain communication in aging and rejuvenation DOI Open Access
Gregor Bieri, Adam B. Schroer, Saul Villeda

et al.

Nature Neuroscience, Journal Year: 2023, Volume and Issue: unknown

Published: Jan. 16, 2023

Language: Английский

Citations

87
Why we need a deeper understanding of the pathophysiology of long COVID DOI
Akiko Iwasaki, David Putrino

The Lancet Infectious Diseases, Journal Year: 2023, Volume and Issue: 23(4), P. 393 - 395

Published: Feb. 15, 2023

Language: Английский

Citations

87
Neuroinflammation and COVID-19 DOI Creative Commons
Abigail Vanderheiden, Robyn S. Klein

Current Opinion in Neurobiology, Journal Year: 2022, Volume and Issue: 76, P. 102608 - 102608

Published: June 29, 2022

Coronavirus disease 2019 (COVID-19) has caused a historic pandemic of respiratory disease. COVID-19 also causes acute and post-acute neurological symptoms, which range from mild, such as headaches, to severe, including hemorrhages. Current evidence suggests that there is no widespread infection the central nervous system (CNS) by SARS-CoV-2, thus what causing disease? Here, we review potential immunological mechanisms driving in patients. We begin discussing implications imbalanced peripheral immunity on CNS function. Next, examine for dysregulation blood-brain barrier during SARS-CoV-2 infection. Last, discuss role myeloid cells may play promoting Combined, highlight innate neuroinflammation suggest areas future research.

Language: Английский

Citations

82
Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study DOI Creative Commons
Manina M. Etter, Tomás A. Martins, Laila Kulsvehagen

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Nov. 9, 2022

Growing evidence links COVID-19 with acute and long-term neurological dysfunction. However, the pathophysiological mechanisms resulting in central nervous system involvement remain unclear, posing both diagnostic therapeutic challenges. Here we show outcomes of a cross-sectional clinical study (NCT04472013) including imaging data corresponding multidimensional characterization immune mediators cerebrospinal fluid (CSF) plasma patients belonging to different Neuro-COVID severity classes. The most prominent signs severe are blood-brain barrier (BBB) impairment, elevated microglia activation markers polyclonal B cell response targeting self-antigens non-self-antigens. decreased regional brain volumes associating specific CSF parameters, however, characterized by cytokine storm presenting non-inflammatory profile. Post-acute syndrome strongly associates distinctive set mediators. Collectively, identify several potentially actionable targets prevent or intervene consequences SARS-CoV-2 infection.

Language: Английский

Citations

76
Severe COVID-19 is associated with molecular signatures of aging in the human brain DOI Open Access
Maria Mavrikaki, Jonathan D. Lee, Isaac H. Solomon

et al.

Nature Aging, Journal Year: 2022, Volume and Issue: 2(12), P. 1130 - 1137

Published: Dec. 5, 2022

Language: Английский

Citations

75
Cognitive Deficits in Long Covid-19 DOI Open Access
Varun Venkataramani, Frank Winkler

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(19), P. 1813 - 1815

Published: Nov. 9, 2022

Language: Английский

Citations

72
Post-COVID cognitive dysfunction: current status and research recommendations for high risk population DOI Creative Commons
Meina Quan,

Xuechu Wang,

Min Gong

et al.

The Lancet Regional Health - Western Pacific, Journal Year: 2023, Volume and Issue: 38, P. 100836 - 100836

Published: July 5, 2023

Summary

Post-COVID cognitive dysfunction (PCCD) is a condition in which patients with history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, usually three months from the onset, exhibit subsequent impairment various domains, and cannot be explained by an alternative diagnosis. While our knowledge risk factors management strategy PCCD still incomplete, it necessary to integrate current epidemiology, diagnosis treatment evidence, form consensus criteria better understand this disease improve management. Identifying vulnerable population providing reliable strategies for effective prevention urgently needed. In paper, we reviewed diagnostic markers, available treatments on disease, formed research recommendation framework population, under background post-COVID period.

Language: Английский

Citations

65
Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization DOI Creative Commons
Maxime Taquet,

Zuzanna Skórniewska,

Adam Hampshire

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(10), P. 2498 - 2508

Published: Aug. 31, 2023

Post-COVID cognitive deficits, including 'brain fog', are clinically complex, with both objective and subjective components. They common debilitating, can affect the ability to work, yet their biological underpinnings remain unknown. In this prospective cohort study of 1,837 adults hospitalized COVID-19, we identified two distinct biomarker profiles measured during acute admission, which predict outcomes 6 12 months after COVID-19. A first profile links elevated fibrinogen relative C-reactive protein deficits. second D-dimer deficits occupational impact. This was mediated by fatigue shortness breath. Neither significantly depression or anxiety. Results were robust across secondary analyses. replicated, specificity COVID-19 tested, in a large-scale electronic health records dataset. These findings provide insights into heterogeneous biology post-COVID

Language: Английский

Citations

65
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID DOI Creative Commons
Jingwei Li, Yun Zhou, Jiechao Ma

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Nov. 1, 2023

Abstract There have been hundreds of millions cases coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2). With the growing population recovered patients, it crucial to understand long-term consequences and management strategies. Although COVID-19 was initially considered an illness, recent evidence suggests that manifestations including but not limited those cardiovascular, respiratory, neuropsychiatric, gastrointestinal, reproductive, musculoskeletal systems may persist long after phase. These persistent manifestations, also referred as COVID, could impact all patients with across full spectrum illness severity. Herein, we comprehensively review current literature on highlighting its epidemiological understanding, vaccinations, organ-specific sequelae, pathophysiological mechanisms, multidisciplinary In addition, psychological psychosomatic factors underscored. Despite these findings diagnostic therapeutic strategies based previous experience pilot studies remain inadequate, well-designed clinical trials should be prioritized validate existing hypotheses. Thus, propose primary challenges concerning biological knowledge gaps efficient remedies well discuss corresponding recommendations.

Language: Английский

Citations

65